Do common ADCY5 (rs11708067) and KCNQ1 (rs2237892) variants increase type 2 diabetes risk by reducing beta‑cell insulin secretion?

Genetic research and functional studies confirm that common variants near the ADCY5 and KCNQ1 genes are significant drivers of type 2 diabetes (T2DM) risk, primarily through the impairment of pancreatic beta-cell insulin secretion.

Clinical and effectiveness evidence

Large-scale genome-wide association studies (GWAS) have consistently linked these specific variants to increased T2DM susceptibility across diverse populations.

• ADCY5 (rs11708067): The risk allele (A) is associated with an increased odds ratio (OR) for type 2 diabetes of approximately 1.23. It is strongly correlated with elevated fasting glucose levels and decreased early-phase insulin response during glucose tolerance tests.
• KCNQ1 (rs2237892): This variant is a major risk factor, particularly in East Asian populations, where it has been associated with T2DM risk with odds ratios as high as 1.59 in certain cohorts. Clinical data show that carriers of the risk allele (C) exhibit significantly lower insulinogenic indices and reduced HOMA-B levels, indicating intrinsic beta-cell dysfunction.

Mechanistic explanations

The elevated diabetes risk is driven by distinct molecular mechanisms that disrupt the normal glucose-stimulated insulin secretion (GSIS) pathway:

• ADCY5 Mechanism: The rs11708067 risk allele resides in an intronic enhancer that, when altered, reduces ADCY5 gene expression in pancreatic islets by up to 64%. ADCY5 encodes adenylate cyclase 5, which produces cyclic AMP (cAMP) in response to glucose. Reduced ADCY5 levels decouple glucose metabolism from the cAMP signals required for insulin exocytosis, resulting in a nearly 39% reduction in glucose-stimulated insulin secretion in laboratory models.
• KCNQ1 Mechanism: KCNQ1 encodes the Kv7.1 voltage-gated potassium channel, essential for regulating the electrical activity of beta-cells. The rs2237892 variant is thought to increase channel activity or expression, leading to premature repolarization of the cell membrane. This shortened electrical activity limits the duration of calcium influx, which is the final trigger for insulin release.

Clinical implications

For individuals carrying these variants, the primary defect is a quantitative reduction in the amount of insulin the pancreas can secrete quickly in response to rising blood sugar (first-phase insulin secretion). Over time, this inability to meet insulin demand leads to postprandial hyperglycemia and eventually clinical type 2 diabetes. Unlike variants that cause insulin resistance in the muscles or liver, these variants represent a primary "failure" of the beta-cell's secretory machinery.

Bottom line

The ADCY5 (rs11708067) and KCNQ1 (rs2237892) variants are validated genetic markers that increase type 2 diabetes risk by reducing the pancreatic beta-cells' ability to secrete insulin in response to glucose, driven by disrupted cAMP signaling and altered potassium channel activity.